2-HOBA Supplementation in People With Elevated Lipoprotein(a)

Part of paid clinical trials in Providence, Rhode Island.

Sponsor
The Miriam Hospital
Study ID
NCT07198009
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Elevated Lp(a)
  • Hyperlipidemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 69 Years
Healthy Volunteers
Not accepted

Interventions

  • 2-HOBA (Hobamine) — DIETARY_SUPPLEMENT
    Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.

Study Details

The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers

Key Dates

Start date
Nov 1, 2025
Status verified
Sep 2025
Primary completion
Mar 31, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: 2-HOBA Supplementation for Elevated Lipoprotein(a)
    Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine) at a dose of 400 mg three times daily with meals for 6 weeks.

Primary Outcome Measure

Change in oxidized phospholipids (OxPL) on circulating lipoprotein(a) [ Time Frame: 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Lipid Clinic at Brown University HealthProvidenceRhode Island02914
Wenliang Song, MD
[email protected]
4014449851
Wenliang Song, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Providence, RI

By research site
Lipid Clinic at Brown University Health· Providence, RI

Related Studies